Navigation

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced ovarian cancer (for recurrent disease only) (Review of TA 91 & TA 222)

Status: In development
Expected date of issue: TBC
Process: MTA
Topic area:
  • Cancer
  • Gynaecology, pregnancy and birth
 

NICE project team

Executive Lead: TBC
Technical Lead: Helen Tucker
Communications manager: Laura Gibson
Project manager:

Bijal Joshi

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 13 March 2013
1st appraisal committee meeting: 04 September 2013
2nd appraisal committee meeting: 06 November 2013
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
09 December 2013

The release of the FAD has been delayed.

We will provide you with an update as soon as we have further information.

12 February 2013

Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride was omitted from the list of relevant interventions for people who are allergic to platinum-based compounds. This omission has been corrected in final scope.

 

Top


 

Key documents

This page was last updated: 20 January 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.